Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current Issue
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
Images in Dermatology
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Media and news
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Images
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Reviewers 2022
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Snippets
Special Article
Specialty Interface
Studies
Study Letter
Study Letters
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Review and Meta-Analysis
Systematic Reviews and Meta-analyses
Systematic Reviews and Meta-analysis
Tables
Technology
Therapeutic Guideline-IADVL
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
Therapy Letters
View Point
Viewpoint
What’s new in Dermatology
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current Issue
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
Images in Dermatology
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Media and news
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Images
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Reviewers 2022
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Snippets
Special Article
Specialty Interface
Studies
Study Letter
Study Letters
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Review and Meta-Analysis
Systematic Reviews and Meta-analyses
Systematic Reviews and Meta-analysis
Tables
Technology
Therapeutic Guideline-IADVL
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
Therapy Letters
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF

Translate this page into:

Letter to the Editor - Therapy Letter
2017:83:6;713-717
doi: 10.4103/ijdvl.IJDVL_1084_16
PMID: 28984626

Treatment of drug-induced hypersensitivity syndrome with cyclosporine

Zhao-Xia Zhang, Bao-Qi Yang, Qing Yang, Mei Wu, Guang-Jin Wang
 Department of Dermatology, Shandong Provincial Institute of Dermatovenereology, Jinan, China

Correspondence Address:
Guang-Jin Wang
Shandong Provincial Institute of Dermatovenereology, Jinan, Shandong 250022
China
Published: 06-Oct-2017
How to cite this article:
Zhang ZX, Yang BQ, Yang Q, Wu M, Wang GJ. Treatment of drug-induced hypersensitivity syndrome with cyclosporine. Indian J Dermatol Venereol Leprol 2017;83:713-717
Copyright: (C)2017 Indian Journal of Dermatology, Venereology, and Leprology

Sir,

Drug-induced hypersensitivity syndrome, also known as drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, is a rare, severe cutaneous adverse reaction characterized by fever, rash, lymphadenopathy, eosinophilia and/or other leukocyte abnormalities, and internal organ involvement. With an estimated mortality rate of 10–20%, timely treatment of drug hypersensitivity syndrome is important.[1] Treatment involves discontinuation of suspected causative medication, supportive care, and systemic corticosteroids. Here, we present a patient with drug hypersensitivity syndrome, who showed suboptimal response to oral corticosteroids and was subsequently treated successfully with a short course of cyclosporine therapy.

A 48-year-old man weighing 60 kg was transferred from a local community hospital history of intermittent fever and rash od one month duration. He had a history of ventricular tachycardia and was prescribed mexiletine 2 months ago. Twenty-four days after the initiation of mexiletine, he developed erythematous edematous papules on the forearms and significant erythema and swelling of the face [Figure - 1]. Erythematous edematous papules gradually progressed to involve the chest, back, and proximal extremities. The patient stopped taking mexiletine and was then prescribed prednisolone 100 mg daily for 9 days, which was then tapered to 70 mg daily for 6 days in the community hospital. He rapidly improved, but he weaned himself off prednisolone on his own volition after discharge. He deteriorated within 11 days after the discontinuation of prednisolone and had a widespread exfoliative dermatitis [Figure - 2] and [Figure - 3]. Subsequently, the patient was admitted to our hospital. Clinical examination did not reveal any mucosal involvement. Lymph nodes in the axillary area were palpable. The patient was febrile with a temperature varying between 37.7°C and 39.5°C. Blood pressure was in the normal range (118/72 mmHg), and pulse rate was 104 beats/min. Laboratory examination revealed hypereosinophilia (3.5 × 103/mm 3) and elevated alanine aminotransferase and lactate dehydrogenase levels (alanine aminotransferase, 97 U/L; lactate dehydrogenase, 505 U/L). Renal function test (serum creatinine, 0.82 mg/dL; blood urea nitrogen, 19.31 mg/dL; serum potassium 5.0 mEq/L) was in the normal range [Table - 1]. The patient denied infectious symptoms, history of psoriasis, or use of other medication before the onset of the rash. A skin biopsy specimen from the right abdomen revealed parakeratosis along with spongiotic dermatitis, lymphocytes, and mild eosinophil infiltration in the upper dermis, which was consistent with a drug hypersensitivity reaction [Figure - 4] and [Figure - 5]. Periodic acid-Schiff (PAS) stain was negative for fungi. Based on the clinical findings, the patient was diagnosed as drug-induced hypersensitivity syndrome, which was confirmed using the RegiSCAR criteria for DRESS and drug-induced hypersensitivity syndrome [Table - 2].[2] The diagnosis of drug-induced hypersensitivity syndrome was clear, so HHV-6 serology was not done in our hospital. Using the Naranjo adverse drug reaction probability scale, we determined that the probability of mexiletine causing the drug-induced hypersensitivity syndrome was probable (score of 5).[3]

Figure 1: Erythematous edematous papules on the forearms; erythema and swelling of the face
Figure 2: Exfoliative dermatitis over the front of the body
Figure 3: Exfoliative dermatitis over the back of the body
Figure 4: Histologic examination shows hyperkeratosis with parakeratosis along with spongiotic dermatitis (H and E, ×20)
Figure 5: Histologic examination shows spongiotic dermatitis, lymphocytes infiltration in the upper dermis (H and E, ×200)
Table 1: Laboratory data of the patient
Table 2: RegiSCAR criteria for drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome and patient data

High blood glucose level of 361.8 mg/dL and strong positive acetone in the urine pointed towards diabetic ketoacidosis, when he was admitted in our hospital. He denied prior history of diabetes mellitus, and blood glucose level was in the normal range during hospitalization in the local community hospital. Diabetic ketoacidosis of the patient was successfully treated by continuous venous drop insulin infusion and fluid replacement. We speculated that diabetes mellitus was the adverse event of corticosteroids. Because systemic corticosteroid therapy was contraindicated, we decided not to use corticosteroids. The patient began a 7-day course of oral cyclosporine at a dose of 5 mg/kg per day divided into twice-daily dosing (150 mg twice daily). Three days after starting treatment with cyclosporine, his eruption started to resolve. After the 7-day course of cyclosporine, his eruption had completely resolved [Figure - 6] and [Figure - 7], and hematological investigation revealed normal alanine aminotransferase concentrations and eosinophil counts (alanine aminotransferase, 50 U/L; eosinophil counts, 0.48 × 103/mm 3) [Table - 1] (37 days after the onset of the skin eruption). Then, the cyclosporine dosage was tapered gradually to 100 mg twice daily for 14 days and 150 mg daily for 20 days. The patient weaned himself off cyclosporine on his own volition and his skin remained quiescent. The total duration of cyclosporine treatment was 41 days. The renal function, blood pressure, and serum lipids remained within the normal range during cyclosporine treatment [Table - 1]. He had no further recurrence of symptoms after 6 months' follow-up.

Figure 6: Skin lesions on the front of the body resolved completely after the 7-day course of cyclosporine
Figure 7: Skin lesions on the back of the body resolved completely after the 7-day course of cyclosporine

We found only 4 cases of this condition, successfully treated with cyclosporine reported in the English literature.[4],[5],[6] Harman et al. reported a patient who developed a reaction to phenytoin and was initially treated with a long tapering course of prednisone. However, after 9 months, she had a recurrence of symptoms. With the patient developing adverse effects of corticosteroids, 4 mg/kg of cyclosporine daily was commenced as a steroid-sparing agent and her skin lesions resolved finally after treatment for 6 months.[4] T-cell production of interleukin-5, leading to eosinophilia may be an important mechanism in the pathogenesis of drug hypersensitivity syndrome. Both corticosteroids and cyclosporine suppress the production of interleukin-5 by T cells. Hence, cyclosporine provides a possible alternative to corticosteroids in the management of drug hypersensitivity. Zuliani et al. reported a patient with drug hypersensitivity syndrome induced by vancomycin, with acute interstitial nephritis and hepatitis, who was initially treated with corticosteroids for 3 weeks without any improvement. After tapering the steroids, hemodialysis and 5-day course of cyclosporine was followed by quick resolution of the skin rash and recovery of renal function.[5] Kirchhof et al. reported two cases who were treated with 3–7 day course of cyclosporine, resulting in rapid and significant clinical improvement.[6] Lee et al. and Daoulah et al. also reported patients who were initially treated with corticosteroids but whose conditions continued to worsen. Despite subsequent treatment with cyclosporine and other immunosuppressive medications, their clinical conditions did not result in clinical resolution.[7],[8]

The first case of mexiletine-induced hypersensitivity syndrome was reported by Higaet al. in 1997.[9] Although mexiletine is prescribed worldwide, most of the previously reported cases of mexiletine-induced hypersensitivity syndrome have been from Japan, suggesting a genetic predisposition.[10] Despite ethnic differences, the Chinese and Japanese populations share much the same genetic background. The pathogenesis of hypersensitivity is unclear, but probably involves a combination of impaired pharmacokinetics and accumulation of drug metabolites, the sequential reactivation of the herpesvirus family and genetic susceptibility conferred by the association with certain human leukocyte antigen (HLA) class I alleles.[6] The immune system is believed to play a central role in the pathogenesis of drug hypersensitivity syndrome. It is well established that certain human leukocyte antigen haplotypes predispose patients to drug hypersensitivity syndrome. These molecules interact with drug metabolites and are ultimately presented to T cells, resulting in T-cell activation. Recent studies also found a close relationship between human herpes virus 6 (HHV-6) and the development of. drug hypersensitivity syndrome It is hypothesized that T-cell activation may stimulate reactivation and replication of dormant herpesviruses within immune cells. Because cyclosporine targets T cells specifically, by downregulating activation of nuclear factor of activated T cells, it might be an appropriate medication to use in the treatment of this condition.[11]

Systemic corticosteroids are the most widely used systemic therapy for drug hypersensitivity syndrome. However, the adverse effects of long-term systemic corticosteroids can be severe.[6] The rapid and successful response in our patient suggests that cyclosporine might be a potential alternative to the traditional long course of systemic corticosteroids in the treatment of drug-induced hypersensitivity syndrome, especially if systemic corticosteroid therapy is contraindicated.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given his consent for his images and other clinical information to be reported in the journal. The patient understand that name and initial will not be published and due efforts will be made to conceal identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Key Research and Development Program of Shandong (2015GSF118126), Young and Middle-Aged Scientists Research Awards of Shangdong Province (BS2013YY010).

Conflicts of interest

There are no conflicts of interest.

References
1.
Criado PR, Criado RF, Avancini JM, Santi CG. Drug reaction with Eosinophilia and Systemic Symptoms (DRESS)/Drug-induced Hypersensitivity Syndrome (DIHS): A review of current concepts. An Bras Dermatol 2012;87:435-49.
[Google Scholar]
2.
Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davidovici BB, Mockenhaupt M, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: Does a DRESS syndrome really exist? Br J Dermatol 2007;156:609-11.
[Google Scholar]
3.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. Amethod for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
[Google Scholar]
4.
Harman KE, Morris SD, Higgins EM. Persistent anticonvulsant hypersensitivity syndrome responding to ciclosporin. Clin Exp Dermatol 2003;28:364-5.
[Google Scholar]
5.
Zuliani E, Zwahlen H, Gilliet F, Marone C. Vancomycin-induced hypersensitivity reaction with acute renal failure: Resolution following cyclosporine treatment. Clin Nephrol 2005;64:155-8.
[Google Scholar]
6.
Kirchhof MG, Wong A, Dutz JP. Cyclosporine treatment of drug-induced hypersensitivity syndrome. JAMA Dermatol 2016;152:1254-7.
[Google Scholar]
7.
Lee JH, Park HK, Heo J, Kim TO, Kim GH, Kang DH, et al. Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome induced by celecoxib and anti-tuberculosis drugs. J Korean Med Sci 2008;23:521-5.
[Google Scholar]
8.
Daoulah A, Alqahtani AA, Ocheltree SR, Alhabib A, Ocheltree AR. Acute myocardial infarction in a 56-year-old female patient treated with sulfasalazine. Am J Emerg Med 2012;30:638.e1-3.
[Google Scholar]
9.
Higa K, Hirata K, Dan K. Mexiletine-induced severe skin eruption, fever, eosinophilia, atypical lymphocytosis, and liver dysfunction. Pain 1997;73:97-9.
[Google Scholar]
10.
Lee SP, Kim SH, Kim TH, Sohn JW, Shin DH, Park SS, et al. Acase of mexiletine-induced hypersensitivity syndrome presenting as eosinophilic pneumonia. J Korean Med Sci 2010;25:148-51.
[Google Scholar]
11.
Shiohara T, Kano Y, Takahashi R, Ishida T, Mizukawa Y. Drug-induced hypersensitivity syndrome: Recent advances in the diagnosis, pathogenesis and management. Chem Immunol Allergy 2012;97:122-38.
[Google Scholar]

Fulltext Views
5,914

PDF downloads
1,395
Show Sections